Clinical trials: Coronavirus Disease 2019
Coronavirus Disease 2019
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections.
- Trial name
- NCT04401436
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
Long COVID, Long Coronavirus Disease 2019 (Covid19)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
- Trial name
- NCT06305793
- Testing
- IVIG (intravenous immunoglobulin), Coordinated Care, Usual Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Kanecia Obie Zimmerman
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
COVID-19 (Coronavirus Disease 2019)
Physiological Finding in Management of COVID 19 Patients
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients.
- Trial name
- COVID-19 (NCT07504341)
- Testing
- physiological parameters
- Where
- 2 sites in Taiwan
- Volunteers
- 15,000 people
- Sponsor
- St. Martin De Porress Hospital
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
Influenza, COVID-19 (Coronavirus Disease 2019)
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older.
- Trial name
- NCT06821061
- Testing
- Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine
- Where
- 31 sites in United States
- Volunteers
- 2,650 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Pneumonia, COVID-19
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in…
- Conditions
- COVID-19 Pneumonia, COVID-19, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05164744
- Testing
- Cardiac MRI, Echocardiogram, 6-minute walk test
- Where
- 3 sites in United States
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077332
- Testing
- Famotidine, Celecoxib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
COVID-19 SARS-CoV-2 Infection, COVID-19
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to…
- Conditions
- COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19)
- Trial name
- NCT06923137
- Testing
- BNT162b2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Coronavirus Disease 2019
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
- Trial name
- NCT04347239
- Testing
- Leronlimab (700mg)
- Where
- 18 sites in United States
- Volunteers
- 484 people
- Sponsor
- CytoDyn, Inc.
COVID-19 (Coronavirus Disease 2019)
Clinical Study of Tanshinone Capsules Against COVID-19
The variation of SARS-CoV-2 has caused many countries to face the problem of multiple outbreaks. Gene mutations can change the transmicity, pathogenicity, and immunogenicity of the virus.
- Trial name
- NCT07123701
- Testing
- Tanshinone capsules
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Liu Shuwen
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
COVID-19: Human Epidemiology and Response to SARS-CoV-2
The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
- Trial name
- HEROS (NCT04375761)
- Testing
- Collection of Biological Samples, Symptom and Exposure Surveys
- Where
- 20 sites in United States
- Volunteers
- 5,599 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019 (COVID-19), Pneumonia
Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
The purpose of this study is to evaluate safety, tolerability, and pharmacodynamics of frespaciguat after administration of multiple doses to participants with COVID-19 pneumonia.
- Conditions
- Coronavirus Disease 2019 (COVID-19), Pneumonia, Hypoxemia
- Trial name
- NCT04425733
- Testing
- Frespaciguat
- Sponsor
- Merck Sharp & Dohme LLC
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Multiple Sclerosis, COVID-19 (Severe Coronavirus Disease 2019)
A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
This nested project of the Swiss Multiple Sclerosis Cohort (SMSC) is to assess the severity of COVID-19 and the magnitude of antibody response after infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in…
- Trial name
- MS COVID-19 (NCT04760990)
- Testing
- data collection, analysis of blood samples
- Where
- 7 sites in Switzerland
- Volunteers
- 1,181 people
- Sponsor
- University Hospital, Basel, Switzerland
Coronavirus Disease 2019 (COVID-19)
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and immunogenicity of AK119, a humanized monoclonal…
- Trial name
- NCT04516564
- Testing
- AK119
- Where
- New Zealand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Akesobio Australia Pty Ltd
Coronavirus Disease-2019 (COVID-19) Prevention
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents.
- Trial name
- HORIZON 2 (NCT05007080)
- Testing
- Ad26.COV2.S
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19 (Coronavirus Disease 2019), Hypoxia
Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of nebulised dornase alfa [2.5 mg BID (bis in die)] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of…
- Trial name
- COVASE (NCT04359654)
- Testing
- Dornase Alfa Inhalation Solution [Pulmozyme]
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University College, London